Evidence map: outcomes by treatment
What published reviews say about each PCOS treatment, for the outcomes women live with: periods, pregnancy, diabetes, hair, skin, mood and quality of life. This page shows where the reviews found no trial evidence.
The rows trials fill most are lab markers. Blood androgens have the most data of any row, because they are easy to measure, not because patients feel them. ../LabAssistant/projects/pcos-outcomes-evidence-map/notes_pill_antiandrogen_lifestyle.md:45-46 The outcomes patients rank highest are the emptiest. ../LabAssistant/projects/pcos-outcomes-evidence-map/notes_metformin_inositol.md:43
Where the reviews found nothing
Each cell lists the treatments for which the reviews read held no trial evidence on that outcome. Taken from the "empty" lists in each part's data file.
| Outcome | No trial evidence found for |
|---|---|
| Quality of life | Any fertility treatment (ovulation-induction drugs, ovarian drilling, IVF strategies); GLP-1 drugs; inositol against placebo; anti-androgens; metformin against placebo with a PCOS-specific questionnaire; the pill against no treatment with a validated PCOS tool |
| Mood, eating, body image | GLP-1 drugs (depression, anxiety, eating, body image); inositol; metformin against placebo (eating disorders, body image); lifestyle (eating disorders, body image); the pill (depression or anxiety as a primary outcome, eating disorders, body image); talking therapy (eating disorders) |
| Skin (acne) | GLP-1 drugs; metformin against placebo; inositol; lifestyle; the pill; anti-androgens; acne treatments studied in PCOS |
| Hair | GLP-1 drugs beyond 6 months or in hirsute women; inositol against placebo; lifestyle; anti-androgens for scalp hair loss; eflornithine cream (any outcome); laser hair removal by clinician score, long term, or on darker skin |
| Diabetes (new cases) | GLP-1 drugs (randomised trials); metformin; inositol; the pill, anti-androgens, cosmetic treatments, lifestyle and talking therapy |
| Periods | Lifestyle (regular cycles); the pill (whether natural cycles return after stopping) |
| Pregnancy and birth | Live birth after lifestyle programmes, GLP-1 drugs before conception, bariatric surgery, or inositol; most fertility comparisons stop at pregnancy; complications for the mother after letrozole, metformin, gonadotrophins or drilling; baby outcomes after metformin, gonadotrophins, drilling, inositol, lifestyle or GLP-1 drugs |
| Long term | GLP-1 drugs beyond 1 year; metformin and inositol beyond about 6 to 12 months |
Three things the map shows
- Few fertility trials follow women to a baby. Letrozole against clomiphene is the one comparison with high-certainty live-birth evidence: odds about 1.7 times higher, 11 trials, 2,060 women. ../LabAssistant/projects/pcos-outcomes-evidence-map/notes_fertility.md:23-24 The Cochrane lifestyle review found no trial that measured live birth. GLP-1 trials (3 trials, 252 women) stop at pregnancy. ../LabAssistant/projects/pcos-outcomes-evidence-map/notes_fertility.md:54-56
- GLP-1 trials are short. No trial ran longer than 32 weeks on the drug. ../LabAssistant/projects/pcos-outcomes-evidence-map/notes_glp1.md:17-18
- How fertility treatment feels is unmeasured. The reviews held no trial that measured how fertility treatment itself affects quality of life or distress. ../LabAssistant/projects/pcos-outcomes-evidence-map/notes_fertility.md:42-44 The same gap shows up in the trial count.
Limits
- Built from reviews, not from the trials. A trial a review left out is not here.
- In the pill, anti-androgen and lifestyle part, most trials have fewer than 100 women, run under a year, and run in one country. ../LabAssistant/projects/pcos-outcomes-evidence-map/notes_pill_antiandrogen_lifestyle.md:67
- The data files live in a sibling project folder (the Lab Assistant), not in this repository.